Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
-
Gloves off, Red run, vested interests: Singapore GP talking points
-
Bills, Eagles lose unbeaten records in day of upsets
-
Muller on target as Vancouver thrash San Jose to go joint top
-
Tokyo soars, yen sinks after Takaichi win on mixed day for Asia
-
China's chip challenge: the race to match US tech
-
UN rights council to decide on creating Afghanistan probe
-
Indonesia sense World Cup chance as Asian qualifying reaches climax
-
ICC to give war crimes verdict on Sudan militia chief
-
Matthieu Blazy to step out as Coco's heir in Chanel debut
-
Only man to appeal in Gisele Pelicot case says not a 'rapist'
-
Appetite-regulating hormones in focus as first Nobel Prizes fall
-
Gisele Pelicot: French rape survivor and global icon
-
Negotiators due in Egypt for Gaza talks as Trump urges quick action
-
'My heart sank': Surging scams roil US job hunters
-
Competition heats up to challenge Nvidia's AI chip dominance
-
UK police to get greater powers to restrict demos
-
Guerrero grand slam fuels Blue Jays in 13-7 rout of Yankees
-
Five-try Bayonne stun champions Toulouse to go top in France
-
Fisk reels in Higgo to win maiden PGA Tour title in Mississippi
-
Aces overpower Mercury for 2-0 lead in WNBA Finals
-
Bayonne stun champions Toulouse to go top in France
-
Greta Thunberg among Gaza flotilla detainees to leave Israel
-
Atletico draw at Celta Vigo after Lenglet red card
-
Trump administration brands US cities war zones
-
Ethan Mbappe returns to haunt PSG as Lille force draw with Ligue 1 leaders
-
Hojlund fires Napoli into Serie A lead as AC Milan held at Juve
-
Vampires, blood and dance: Bollywood horror goes mainstream
-
Broncos rally snaps Eagles unbeaten record, Ravens slump deepens
-
Former NFL QB Sanchez charged after allegedly attacking truck driver
-
France unveils new government amid political deadlock
-
Hojlund fires Napoli into Serie A lead ahead of AC Milan's showdown with Juve
-
Child's play for Haaland as Man City star strikes again
-
India crush Pakistan by 88 runs amid handshake snub, umpiring drama
-
Hojlund fires Napoli past Genoa and into Serie A lead
-
Sevilla rout 'horrendous' Barca in Liga thrashing
-
Haaland fires Man City to win at Brentford, Everton end Palace's unbeaten run
-
Haaland extends hot streak as Man City sink Brentford
-
Italy working hard to prevent extra US tariffs on pasta
-
Sinner out of Shanghai Masters as Djokovic battles into last 16
-
Swift rules N. America box office with 'Showgirl' event
-
Ryder Cup hero MacIntyre wins Alfred Dunhill Links on home soil
-
Republicans warn of pain ahead as US shutdown faces second week
-
Sevilla rout champions Barca in shock Liga thrashing
-
Norris-Piastri clash overshadows McLaren constructors' title win
-
Trump administration declares US cities war zones
-
Bad Bunny takes aim at Super Bowl backlash in 'SNL' host gig
-
El Khannouss fires Stuttgart into Bundesliga top four
-
Insatiable Pogacar romps to European title
-
Newcastle inflict more pain on Postecoglou, Everton end Palace's unbeaten run
-
Daryz wins emotional and thrilling Prix de l'Arc de Triomphe
NYSE - LSE
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow morning.
A copy of the original press release announcing data can be found here.
A copy of the presentation to be reviewed can be found here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and the treatment of chronic kidney disease.
For more information on Revelation, please visit https://www.revbiosciences.com.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: [email protected]
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: [email protected]
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
P.Stevenson--AMWN
